Related Experiment Video
Updated: Mar 3, 2026
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: Immunogenicity and
Setareh Haghighat1, Seyed Davar Siadat2, Seyed Mehdi Rezayat Sorkhabadi3
1Department of Microbiology, Faculty of Advanced Sciences and Technology, Pharmaceutical Sciences Branch, Islamic Azad University (IAUPS), Tehran, Iran.
Abstract:
Methicillin-resistant Staphylococcus aureus infections are focal and development of an effective vaccine can help to control this infection. Here, recombinant PBP2a was studied in mouse model. Following the preparation of recombinant PBP2a, Balb/c mice were injected subcutaneously with 20 μg of r-PBP2a formulated in Freund's adjuvant three times with three weeks intervals with proper control group. Total and specific isotype antibodies were evaluated on sera by ELISA. Opsonophagocytic activity was also investigated on the sera samples. Intraperitonealchallenge with a sub-lethal dose of MRSA (5 × 108 CFU) was done in experimental mice. Following that, the number of bacteria from kidneys of experimental mice were determined. Survival rate was recorded for 60 days. Significant increase of antibody with high level of IgG1, IgG2a and IgG2b isotypes was demonstrated in vaccinated mice versus the control group (P < 0.005). The bacterial load in the kidneys from immunized mice was 1000 times less thancontrol group (PBS) and opsonophagocytic activity of immunized mice sera significantly increased (P < 0.0001). Finally the life span of immunized mice after bacterial challenge was extended versus control mice. These results may indicate the capacity of PBP2a as a candidate vaccine to control the MRSA infections.
Insights
Developing a vaccine against Methicillin-resistant Staphylococcus aureus (MRSA) is crucial. This study shows that a recombinant PBP2a vaccine candidate significantly reduced MRSA bacterial load and improved survival in mice.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a significant public health threat.
- Focal nature of MRSA infections necessitates targeted control strategies, including vaccine development.
Purpose of the Study:
- To evaluate the efficacy of a recombinant PBP2a vaccine candidate against MRSA infections in a mouse model.
- To assess the immunogenic and protective responses induced by the r-PBP2a vaccine.
Main Methods:
- Balb/c mice were immunized with recombinant PBP2a (r-PBP2a) in Freund's adjuvant.
- Antibody levels (total and isotype-specific), opsonophagocytic activity, bacterial load in kidneys, and survival rates were assessed post-MRSA challenge.
Main Results:
- Vaccinated mice showed significantly increased levels of total antibodies and IgG1, IgG2a, and IgG2b isotypes.
- A 1000-fold reduction in kidney bacterial load was observed in immunized mice compared to controls.
- Opsonophagocytic activity was significantly enhanced, and survival rates were extended in the vaccinated group.
Conclusions:
- Recombinant PBP2a demonstrates potential as a vaccine candidate for controlling MRSA infections.
- The study highlights the immunogenicity and protective capacity of r-PBP2a against MRSA challenge.
More Related Videos
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011